Skip to main content
PMC home page
The BMJ logoLink to The BMJ
. 1991 Feb 2;302(6771):259–262. doi: 10.1136/bmj.302.6771.259

Hormone replacement therapy and survival after surgery for ovarian cancer.

R A Eeles 1, S Tan 1, E Wiltshaw 1, I Fryatt 1, R P A'Hern 1, J H Shepherd 1, C L Harmer 1, P R Blake 1, C E Chilvers 1
PMCID: PMC1668928  PMID: 1998789

Abstract

OBJECTIVE--To evaluate whether hormone replacement therapy affects survival in women who have undergone bilateral salphingo-oophorectomy because of epithelial ovarian cancer. DESIGN--Retrospective analysis by review of patients' notes and questionnaires completed by general practitioners to compare the overall survival and disease free survival in patients with ovarian cancer who did or did not receive hormone replacement therapy after diagnosis. Data were analysed by Cox regression, with hormone replacement therapy as a time dependent covariate because patients who received hormone replacement did so at different times after diagnosis. SETTING--Gynaecological oncology unit of Royal Marsden Hospital. PATIENTS--373 patients aged 50 years or younger who attended the hospital from 1972 to 1988. All of the women had undergone bilateral salpingoophorectomy for epithelial ovarian cancer. In all, 78 had received hormone replacement therapy, starting at a median of four months after diagnosis. INTERVENTION--A questionnaire was sent to the general practitioners of all patients who were not recorded as having received hormone replacement therapy. MAIN OUTCOME MEASURES--Overall survival and disease free survival. RESULTS--There was no significant difference in survival between women receiving hormone replacement therapy and those not receiving it after accounting for the effects of other known prognostic factors (stage of cancer, differentiation of tumour, histological results, and time to relapse). The relative risk of dying in those who received hormone replacement therapy was 0.73 (95% confidence interval 0.44 to 1.20). In addition, there was no significant difference in disease free survival (relative risk in those receiving hormone replacement therapy was 0.90; 95% confidence interval 0.52 to 1.54). CONCLUSIONS--This study shows that hormone replacement therapy is unlikely to have a detrimental effect on the prognosis of patients with ovarian cancer, but this would be shown conclusively only by a randomised controlled trial.

Full text

PDF
259

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson J. R., Cain K. C., Gelber R. D., Gelman R. S. Analysis and interpretation of the comparison of survival by treatment outcome variables in cancer clinical trials. Cancer Treat Rep. 1985 Oct;69(10):1139–1146. [PubMed] [Google Scholar]
  2. Barrett-Connor E. Postmenopausal estrogen replacement and breast cancer. N Engl J Med. 1989 Aug 3;321(5):319–320. doi: 10.1056/NEJM198908033210510. [DOI] [PubMed] [Google Scholar]
  3. Colditz G. A., Willett W. C., Stampfer M. J., Rosner B., Speizer F. E., Hennekens C. H. Menopause and the risk of coronary heart disease in women. N Engl J Med. 1987 Apr 30;316(18):1105–1110. doi: 10.1056/NEJM198704303161801. [DOI] [PubMed] [Google Scholar]
  4. Coope J., Thomson J. M., Poller L. Effects of "natural oestrogen" replacement therapy on menopausal symptoms and blood clotting. Br Med J. 1975 Oct 18;4(5989):139–143. doi: 10.1136/bmj.4.5989.139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cramer D. W., Hutchison G. B., Welch W. R., Scully R. E., Ryan K. J. Determinants of ovarian cancer risk. I. Reproductive experiences and family history. J Natl Cancer Inst. 1983 Oct;71(4):711–716. [PubMed] [Google Scholar]
  6. Cummings S. R., Kelsey J. L., Nevitt M. C., O'Dowd K. J. Epidemiology of osteoporosis and osteoporotic fractures. Epidemiol Rev. 1985;7:178–208. doi: 10.1093/oxfordjournals.epirev.a036281. [DOI] [PubMed] [Google Scholar]
  7. Hartge P., Hoover R., McGowan L., Lesher L., Norris H. J. Menopause and ovarian cancer. Am J Epidemiol. 1988 May;127(5):990–998. doi: 10.1093/oxfordjournals.aje.a114902. [DOI] [PubMed] [Google Scholar]
  8. Henderson B. E., Ross R. K., Lobo R. A., Pike M. C., Mack T. M. Re-evaluating the role of progestogen therapy after the menopause. Fertil Steril. 1988 May;49(5 Suppl 2):9S–15S. [PubMed] [Google Scholar]
  9. Hildreth N. G., Kelsey J. L., LiVolsi V. A., Fischer D. B., Holford T. R., Mostow E. D., Schwartz P. E., White C. An epidemiologic study of epithelial carcinoma of the ovary. Am J Epidemiol. 1981 Sep;114(3):398–405. doi: 10.1093/oxfordjournals.aje.a113207. [DOI] [PubMed] [Google Scholar]
  10. Horsman A., Gallagher J. C., Simpson M., Nordin B. E. Prospective trial of oestrogen and calcium in postmenopausal women. Br Med J. 1977 Sep 24;2(6090):789–792. doi: 10.1136/bmj.2.6090.789. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hunt K., Vessey M., McPherson K., Coleman M. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gynaecol. 1987 Jul;94(7):620–635. doi: 10.1111/j.1471-0528.1987.tb03166.x. [DOI] [PubMed] [Google Scholar]
  12. Kühnel R., Delemarre J. F., Rao B. R., Stolk J. G. Correlation of multiple steroid receptors with histological type and grade in human ovarian cancer. Int J Gynecol Pathol. 1987;6(3):248–256. doi: 10.1097/00004347-198709000-00006. [DOI] [PubMed] [Google Scholar]
  13. La Vecchia C., Liberati A., Franceschi S. Noncontraceptive estrogen use and the occurrence of ovarian cancer. J Natl Cancer Inst. 1982 Dec;69(6):1207–1207. [PubMed] [Google Scholar]
  14. Richelson L. S., Wahner H. W., Melton L. J., 3rd, Riggs B. L. Relative contributions of aging and estrogen deficiency to postmenopausal bone loss. N Engl J Med. 1984 Nov 15;311(20):1273–1275. doi: 10.1056/NEJM198411153112002. [DOI] [PubMed] [Google Scholar]
  15. Tobias J. S., Griffiths C. T. Management of ovarian carcinoma. Current concepts and future prospects (first of two parts). N Engl J Med. 1976 Apr 8;294(15):818–822. doi: 10.1056/NEJM197604082941506. [DOI] [PubMed] [Google Scholar]
  16. Tzonou A., Day N. E., Trichopoulos D., Walker A., Saliaraki M., Papapostolou M., Polychronopoulou A. The epidemiology of ovarian cancer in Greece: a case-control study. Eur J Cancer Clin Oncol. 1984 Aug;20(8):1045–1052. doi: 10.1016/0277-5379(84)90107-x. [DOI] [PubMed] [Google Scholar]
  17. Weiss N. S., Lyon J. L., Krishnamurthy S., Dietert S. E., Liff J. M., Daling J. R. Noncontraceptive estrogen use and the occurrence of ovarian cancer. J Natl Cancer Inst. 1982 Jan;68(1):95–98. [PubMed] [Google Scholar]
  18. Whitehead M., Lobo R. A. Consensus conference: Progestagen use in postmenopausal women. Lancet. 1988 Nov 26;2(8622):1243–1244. doi: 10.1016/s0140-6736(88)90824-0. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES